Firibastat in Treatment-resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.

Also called NCT04277884

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 515 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04277884
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Czechia, France, Germany, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04277884. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-25 (actual); primary completion 2022-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Firibastat in Treatment-resistant Hypertension
Acronym
FRESH
Condition
Hypertension
Intervention (Drug)
Firibastat
Intervention (Drug)
Placebo
Lead sponsor
Quantum Genomics SA (class: industry)

Record details

Record id
cardio:ct-nct04277884
Content hash
9395ba26788b186373dcc90f40b714910c985795ca5bad0625dbe7abed0daa7d